The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan

碩士 === 高雄醫學大學 === 藥學研究所碩士在職專班 === 94 === Background: Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combi...

Full description

Bibliographic Details
Main Authors: Wei-Hsin Ko, 柯維信
Other Authors: 吳信昇
Format: Others
Language:zh-TW
Published: 2006
Online Access:http://ndltd.ncl.edu.tw/handle/84910107206325271259
id ndltd-TW-094KMC05551038
record_format oai_dc
spelling ndltd-TW-094KMC055510382015-12-16T04:32:13Z http://ndltd.ncl.edu.tw/handle/84910107206325271259 The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan 台灣某三家區域教學醫院C型肝炎以peginterferonalfa2b與ribavirin合併治療結果分析 Wei-Hsin Ko 柯維信 碩士 高雄醫學大學 藥學研究所碩士在職專班 94 Background: Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combination with ribavirin. The duration of treatment may be individualized by the genotype. Patients with genotype 1 required treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotype 2 or 3 seem to be adequately treated with a low dose of ribavirin. Objectives: The objectives of this study are to analyze the predictive factors of sustained response and the relationship medication dose and adverse reaction, so as to provide references of treatment. Methods: Data was collected from an outpatient computerized prescription data base of three regional hospitals from January 1, 2002, through December 31, 2005. Patients who were diagnosed as hepatitis C and were treated by combination of peginterferon alfa 2b and ribavirin were included. The data analysis includes the relationship between therapeutic response and genotype, age, stage of fibrosis; the relationship between abnormality of laboratory data and ribavirin dose and peginterferon alfa 2b dose. Statistical methods used in this study are chi-square test, independent-samples T test and paired T test. We used SPSS (statistical package for social science) 8.0 for Windows software to compile statistics. Results and conclusions: After six months finished treatment, 46 patients are of the sustained biochemical response (47.6 % for intention-to-treat, 60.6 % for per protocol). In total 91 treated patients, there are 66 patients with abnormal white blood cell count (75.0 %), 65 patients (73.9 %) with abnormal hemoglobulin, 27 patients (64.2 %) with abnormal absolute neutrophil count, 31 patients (47.7 %) with abnormal platelet count, 8 patients (10.8%) with abnormal total bilirubin, and 2 patients (2.5 %) with abnormal thyroid stimulating hormone. The response of treatment is related to age and the genotype of hepatitis C virus (P < 0.05), but not related to gender and weight (P > 0.05). We can not conclude if the occurrences of abnormal laboratory data are related to the dosage of peginterferon alfa 2b and ribavirin. 吳信昇 2006 學位論文 ; thesis 59 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 高雄醫學大學 === 藥學研究所碩士在職專班 === 94 === Background: Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combination with ribavirin. The duration of treatment may be individualized by the genotype. Patients with genotype 1 required treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotype 2 or 3 seem to be adequately treated with a low dose of ribavirin. Objectives: The objectives of this study are to analyze the predictive factors of sustained response and the relationship medication dose and adverse reaction, so as to provide references of treatment. Methods: Data was collected from an outpatient computerized prescription data base of three regional hospitals from January 1, 2002, through December 31, 2005. Patients who were diagnosed as hepatitis C and were treated by combination of peginterferon alfa 2b and ribavirin were included. The data analysis includes the relationship between therapeutic response and genotype, age, stage of fibrosis; the relationship between abnormality of laboratory data and ribavirin dose and peginterferon alfa 2b dose. Statistical methods used in this study are chi-square test, independent-samples T test and paired T test. We used SPSS (statistical package for social science) 8.0 for Windows software to compile statistics. Results and conclusions: After six months finished treatment, 46 patients are of the sustained biochemical response (47.6 % for intention-to-treat, 60.6 % for per protocol). In total 91 treated patients, there are 66 patients with abnormal white blood cell count (75.0 %), 65 patients (73.9 %) with abnormal hemoglobulin, 27 patients (64.2 %) with abnormal absolute neutrophil count, 31 patients (47.7 %) with abnormal platelet count, 8 patients (10.8%) with abnormal total bilirubin, and 2 patients (2.5 %) with abnormal thyroid stimulating hormone. The response of treatment is related to age and the genotype of hepatitis C virus (P < 0.05), but not related to gender and weight (P > 0.05). We can not conclude if the occurrences of abnormal laboratory data are related to the dosage of peginterferon alfa 2b and ribavirin.
author2 吳信昇
author_facet 吳信昇
Wei-Hsin Ko
柯維信
author Wei-Hsin Ko
柯維信
spellingShingle Wei-Hsin Ko
柯維信
The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
author_sort Wei-Hsin Ko
title The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
title_short The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
title_full The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
title_fullStr The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
title_full_unstemmed The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
title_sort analysis of hepatitis c treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in taiwan
publishDate 2006
url http://ndltd.ncl.edu.tw/handle/84910107206325271259
work_keys_str_mv AT weihsinko theanalysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan
AT kēwéixìn theanalysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan
AT weihsinko táiwānmǒusānjiāqūyùjiàoxuéyīyuàncxínggānyányǐpeginterferonalfa2byǔribavirinhébìngzhìliáojiéguǒfēnxī
AT kēwéixìn táiwānmǒusānjiāqūyùjiàoxuéyīyuàncxínggānyányǐpeginterferonalfa2byǔribavirinhébìngzhìliáojiéguǒfēnxī
AT weihsinko analysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan
AT kēwéixìn analysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan
_version_ 1718149389078233088